Physiological predictors of peak inspiratory flow using Observed lung function results (POROS): evaluation at discharge among patients hospitalized for a COPD exacerbation

This article was published in the following Dove Press journal:
International Journal of COPD

David B Price,1,2 Sen Yang,1 Simon Wan Yau Ming,1 Antony Hardjojo,1 Claudia Cabrera,3,4 Andriana I Papaioannou,5 Stelios Loukides,5 Vicky Kritikos,6 Sinthia Z Bosnic-Anticevich,6 Victoria Carter,7 Paul M Dorinsky8

1Observational and Pragmatic Research Institute Pte Ltd, Singapore, Singapore; 2Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK; 3Global Medical Affairs, AstraZeneca R and D, Mölndal, Sweden; 4Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden; 52nd Respiratory Medicine Department, Medical School, National and Kapodistrian University of Athens, Attikon General Hospital, Athens, Greece; 6Woolcock Institute of Medical Research, Quality Use of Respiratory Medicines Group, School of Medical Sciences, University of Sydney, Glebe, Australia; 7Optimum Patient Care, Cambridge, UK; 8Pearl – a member of the AstraZeneca Group, Durham, NC, USA

Background: Peak inspiratory flow (PIF) as generated through the resistance of a dry powder inhaler (DPI) device is a critical patient-dependent maneuver impacting the success of DPI medication delivery. Despite its importance, it is not routinely measured in clinical practice. Little is currently known about the relationship, if any, between PIF through DPI devices, routine spirometry and disease outcomes.

Aim: The aim of this study was to identify potential predictors of PIF for different DPIs from spirometric parameters and patient characteristics and explore the association between PIF and follow-up events.

Patients and methods: A retrospective observational study at discharge among patients hospitalized for a COPD exacerbation at Attikon hospital, Athens, Greece. Spirometry was performed using an Easy on-PC™ spirometer. PIF was measured through four DPI resistances using the In-Check™ DIAL. Regression analyses were used to investigate the association between PIF through resistances and spirometric parameters obtained at discharge, comorbidities and demographic parameters.

Results: Forty-seven COPD patients (mean ±SD, age 71 ±9 years, 72% males, 51% current smokers) were included in this study. Overall, 85% and 15% were classified as GOLD (2017) groups D and C, respectively. Most prevalent comorbidities were hypertension (70%) and cardiovascular disease (53%). In the final regression model, higher PIF was significantly associated with the following: higher FEV1, % predicted peak expiratory flow (PEF) for Turbohaler® (R-squared value 0.374); higher FEV1 and diagnosis of gastroesophageal reflux disease (GERD) for Aerolizer® (R-squared value 0.209) and higher FEV1, younger age and diagnosis of ischemic heart disease (IHD) for Diskus® (R-squared value 0.350). However, R-squared values for all three devices were weak (<0.4).

Conclusion: The study did not provide evidence to support the use of surrogate measurements for PIF through device resistance, which could assist in determining the appropriateness of inhaler device type. Although PIF measurement is feasible in patients at discharge and could be a valuable addition to the standard of care in COPD management, it needs to be measured directly.

Keywords: hospital admission, COPD, dry powder inhaler devices, inhaler technique, resistance, spirometry

Introduction

COPD is a progressive, multicomponent and complex disease. Its association with multiple comorbidities increases the overall disease burden and health care costs.1-3
Advanced stages of COPD are accompanied by an increasing frequency and severity of exacerbations, which accelerate the decline in lung function, decrease health status and quality of life and are a leading cause of hospitalization and mortality. Management is aimed at both improving symptom control and preventing or reducing exacerbations.

Inhaled medications are the mainstay of pharmacological treatment of COPD, allowing for the rapid delivery of small doses of medication directly to the airways and reducing the risk of adverse effects due to lower systemic exposure vs oral administration. Effective inhaled treatments for COPD include bronchodilators and corticosteroids, most commonly delivered using pressurized metered dose inhalers (pMDIs) and dry powder inhalers (DPIs), each of which have different degrees of airflow resistance. These device types require different inhalation techniques to ensure optimal medication delivery. With pMDIs, coordination of actuation with slow and steady inspiration is required for adequate lung deposition. In contrast, successful drug delivery from a DPI requires an initial fast inhalation to generate sufficient peak inspiratory flow (PIF) through the device to overcome the resistance within the device and is dependent on the patient’s level of effort and respiratory muscle strength. An optimal PIF which can be sustained for 2–3 seconds is needed to deaggregate drug particles and disperse the powder into finer particles suitable for lung deposition. Furthermore, the inspiratory effort required for successful drug delivery varies depending on the resistance within the DPI device. PIF as generated through the mouthpiece of a DPI device is a critical patient-dependent maneuver impacting the success of DPI medication delivery.

Poor inhaler technique is common among COPD patients, up to 68% using their inhalers incorrectly and nearly 30% failing to achieve a forceful inspiratory flow depending on the DPI device. In the CRITIKAL study, inhaler technique errors related to inspiratory effort were found to be common, and actuation before inhalation in pMDI users and insufficient inspiratory effort in DPI users were shown to be frequent critical errors associated with poor asthma outcomes. Inhaler misuse can also lead to reduced effectiveness of treatment, influence patient adherence to therapy and has been associated with increased health care utilization and poor COPD outcomes. Thus, when initiating and monitoring therapy through a DPI device, it is important to check whether a patient has the ability to inhale with sufficient inspiratory effort to use a specific DPI device so that they receive the optimal dose of medication. Despite the important role of PIF in the context of DPI technique, it is not routinely measured in clinical practice. Part of this may be due to the fact that PIF from spirometry has been used as a surrogate measure of PIF through a device, but spirometric PIF is at zero resistance and thus may be misleading. Little is currently known about the relationship, if any, between PIF through DPI devices, routine spirometry and disease outcomes.

Evidence is needed to better understand the relationship between PIF, proper device use and clinical outcomes among COPD patients. Recently, a retrospective study found that COPD patients with suboptimal PIFs that were obtained at zero resistance had fewer days to readmission after discharge for a severe exacerbation. In addition, while a limited number of studies have measured PIFs against different imposed resistance levels in stable COPD outpatients, and in patients at discharge following a COPD exacerbation, results from these studies indicate that suboptimal PIFs were prevalent in these two subgroups. Since PIF through a DPI device is not routinely measured in clinical practice, it is important to determine whether or not routine lung function tests coupled with routine demographic and clinical parameters such as severity of breathlessness and comorbidities can contribute to the prediction of PIF through a DPI or whether PIF needs to be measured directly. Finding a proxy for PIF through a DPI would be valuable in determining the appropriateness of inhaler device type and improving COPD treatment strategies.

Therefore, the present study was designed to identify whether predictors of PIF for different DPIs among inpatients at the time of discharge could be determined based on spirometric parameters and patient characteristics and to explore the association between PIF and follow-up events, including time to an exacerbation following discharge with or without hospitalization.

Materials and methods

Study design

This retrospective observational study used data from patients with COPD admitted to a single hospital in Greece for a COPD exacerbation between January 2016 and September 2016. Baseline data were collected over a 1-year period prior to discharge (index date), and patients were followed until death or until April 2017 after discharge (outcome period) using primary and secondary care data. Ethical approval was obtained from the Attikon University Hospital, Chaidari, Athens, Greece (approval number 575/7-1-15). All participants gave written informed consent.

Study population

Patients were included in the study if all the following inclusion criteria were met: they had a diagnosis of COPD on
admission to the Attikon hospital respiratory unit in Athens (Greece) based on the GOLD (2017) strategy; they were discharged from hospital (index date) to the community following the hospital admission for a COPD exacerbation, and they had spirometry during admission and PIFs obtained through an In-Check™ DIAL on the same day of discharge. Patients were excluded from the study if they had a diagnosis of asthma or any chronic respiratory disease other than COPD, or their PIF measurements were not obtained on the same day of discharge.

Data sources
The study used anonymized patient data from Attikon hospital, Athens, Greece. The database is a combination of electronic health records of patients admitted to hospital with a COPD-related exacerbation and prescription data obtained from a database that includes primary care prescriptions. The database includes information on diagnosis of comorbidities, lung function tests, previous medications (gathered via the national electronic prescription system), inpatient prescriptions, discharge medications, non-invasive ventilation and length of hospital stay. Post bronchodilator (PB) lung function tests were recorded in this database using a portable PC-based spirometer, the Easy on-PC™ Spirometer (ndd Medizintechnik, Zurich, Switzerland), which meets all the American Thoracic Society/European Respiratory Society (ATS/ERS) recommendations for diagnostic spirometers. Lung function tests were performed according to the ATS/ERS 2005 guidelines. The data set also includes PB PIF measurements through the In-Check DIAL (Clement Clarke International Ltd., Harlow, UK), which is a portable inspiratory flow meter with an adjustable dial that can be set at zero resistance or set to simulate the resistance characteristics of common DPIs. It was set to simulate the following four DPI devices with varying resistance levels: low – Aerolizer® (Merck & Co., Inc., Whitehouse Station, NJ, USA); medium/low – Diskus® (GlaxoSmithKline plc, London, UK); medium/high – Turbohaler® (AstraZeneca plc, London, UK or Södertälje, Sweden) and high – Handihaler® (Boehringer Ingelheim, Ingelheim, Germany). The In-Check DIAL is capable of measuring inspiratory flow rates between 0 and 120 L/min and is calibrated with an ATS waveform generator, with a reported accuracy rate of 10% or 10 L/min.

Study variables
Demographic data were collected including age (closest to the index date), gender, body mass index (BMI) (closest to the index date) and smoking status (closest to the index date) (further details and variable definitions are provided in Supplementary material S1 and Table 1). Comorbidities were recorded any time prior to the index date – as a yes/no response in the study-specific data collection form based on

Table 1 Unadjusted associations between spirometric parameters and PIF through each In-Check™ DIAL resistance setting

<table>
<thead>
<tr>
<th>In-Check DIAL resistance setting</th>
<th>Covariates</th>
<th>Simple linear regression</th>
<th>R-squared statistic</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Unstandardized coefficient B (95% CI)</td>
<td></td>
</tr>
<tr>
<td>Aerolizer®</td>
<td>FEV,</td>
<td>18.4 (2.6, 34.3)</td>
<td>0.109</td>
</tr>
<tr>
<td></td>
<td>FEV, /FVC</td>
<td>20.6 (−31.2, 72.5)</td>
<td>0.014</td>
</tr>
<tr>
<td></td>
<td>% predicted FVC</td>
<td>0.40 (−0.09, 0.89)</td>
<td>0.056</td>
</tr>
<tr>
<td></td>
<td>% predicted FEV,</td>
<td>0.29 (−0.11, 0.69)</td>
<td>0.045</td>
</tr>
<tr>
<td></td>
<td>log(PF25-75)</td>
<td>8.4 (−3.5, 20.3)</td>
<td>0.046</td>
</tr>
<tr>
<td></td>
<td>% predicted PEF</td>
<td>0.47 (0.10, 0.84)</td>
<td>0.133</td>
</tr>
<tr>
<td>Diskus®</td>
<td>FEV,</td>
<td>19.9 (6.8, 33.0)</td>
<td>0.172</td>
</tr>
<tr>
<td></td>
<td>FEV, /FVC</td>
<td>23.7 (−20.5, 67.9)</td>
<td>0.025</td>
</tr>
<tr>
<td></td>
<td>% predicted FVC</td>
<td>0.39 (−0.03, 0.81)</td>
<td>0.071</td>
</tr>
<tr>
<td></td>
<td>% predicted FEV,</td>
<td>0.29 (−0.05, 0.63)</td>
<td>0.061</td>
</tr>
<tr>
<td></td>
<td>log(PF25-75)</td>
<td>7.4 (−2.6, 17.4)</td>
<td>0.050</td>
</tr>
<tr>
<td></td>
<td>% predicted PEF</td>
<td>0.41 (0.09, 0.74)</td>
<td>0.134</td>
</tr>
<tr>
<td>Turbohaler®</td>
<td>FEV,</td>
<td>16.1 (7.2, 24.9)</td>
<td>0.230</td>
</tr>
<tr>
<td></td>
<td>FEV, /FVC</td>
<td>28.7 (−1.4, 58.8)</td>
<td>0.076</td>
</tr>
<tr>
<td></td>
<td>% predicted FVC</td>
<td>0.39 (0.11, 0.67)</td>
<td>0.151</td>
</tr>
<tr>
<td></td>
<td>% predicted FEV,</td>
<td>0.35 (0.13, 0.58)</td>
<td>0.180</td>
</tr>
<tr>
<td></td>
<td>log(PF25-75)</td>
<td>9.0 (2.4, 15.5)</td>
<td>0.152</td>
</tr>
<tr>
<td></td>
<td>% predicted PEF</td>
<td>0.43 (0.22, 0.63)</td>
<td>0.294</td>
</tr>
</tbody>
</table>

Note: Bold values represent significant univariate associations between spirometric parameters and PIF through each imposed resistance setting.

Abbreviations: FEV, forced expiratory volume; FVC, forced vital capacity; PEF, peak expiratory flow; PIF, peak inspiratory flow.
information from the database or patient-reported outcomes. Lung function tests were recorded every day during hospitalization (measurement closest to the day of PIF measurement was used as baseline) and included the following: FEV₁; FVC; FEV₁/FVC; percent predicted FEV₁; forced expiratory flow 25–75 (FEF₂₅₋₇₅) and peak expiratory flow (PEF). PIF measurements through In-Check DIAL set at different resistances were obtained by resident doctors on the day of discharge. Patients were instructed to breathe in “fast and hard” through the device following exhalation to residual volume (RV), and the best PIF out of three consecutive measurements was recorded.

The following variables were recorded 1 year prior to the index date (ie, during the baseline year): GOLD 2017 group classification; Modified British Medical Research Council (mMRC) score; Modified BORG dyspnea scale; and type of COPD exacerbation according to Anthonisen criteria and exacerbation severity (variable definitions are provided in Supplementary material S1; Table 1). The following prescriptions were recorded during the baseline year from the prescription database: short-acting β₂ agonist (SABA) and/or short-acting muscarinic antagonist (SAMA); long-acting muscarinic antagonist (LAMA); long-acting β₂ agonist (LABA); inhaled corticosteroids (ICSs) and fixed dose combinations of ICS/LABA, LABA/LAMA and SABA/SAMA.

Data analyses
Summary statistics were calculated for baseline variables including mean, SD, median, IQR, minimum and maximum for continuous variables and counts and percentages for categorical variables. Doses of ICS containing medication were categorized into low, medium and high (Supplementary material S1; Table 2). The last recorded measurement before discharge was summarized for all lung function tests and PIFs through In-Check DIAL. Box plots were used to depict the distributions of PIF by categorical baseline variables (eg, gender, smoking status and comorbidities). Correlation matrices were used to examine the relationship between PIF and spirometric parameters and additional baseline covariates. Potential covariates were chosen based on the examination of the box plots and correlation matrices.

An exploratory analysis of the association between PIF and exacerbations following discharge was performed, and scatter plots of time to event against PIF were examined for each resistance setting. Outcomes included the following: acute exacerbation following discharge with hospitalization; acute exacerbation following discharge without hospitalization and no acute exacerbations from the time of discharge to data collection. Kaplan–Meier plots of the probability of remaining hospitalization-free following discharge for each resistance setting and by PIF categories (<30 and ≥30 L/min for Handihaler; <60 and ≥60 L/min for Aerolizer, Diskus and Turbohaler) were also examined. An exploratory analysis of time to acute exacerbation with hospitalization by baseline COPD medication (categorized by medication class) groups was also performed. The baseline medication groups were as follows: stable – patients who did not change medication; additional – those patients who received additional therapy and dropped – those patients who dropped therapy. All statistical analyses were performed using SAS version 9.4 and R version 3.4.0.4.

Results
Patient population
A flow diagram of the participant screening and selection process is summarized in Figure 1. The final study sample included 47 COPD patients over the study time period. The mean (±SD) age of patients was 71 (±9) years with 35 (75%) patients aged ≥65 years, 34 (72%) were male, 17 (36%) had a BMI of ≥30 and over half were current smokers. The median (IQR) FEV₁ was 1.5 (1.2, 2.1) L and the median (IQR) FEF₂₅₋₇₅ was 1.1 (0.8, 1.5) L/min. The median (IQR) respiratory rate was 18 (13, 21) breaths per minute (bpm), the median (IQR) modified Modified BORG dyspnea score was 2 (2, 3) and the median (IQR) mMRC was 2 (2, 3).

Table 2 Multivariable association of spirometric parameters with PIF through each In-Check™ DIAL resistance setting

<table>
<thead>
<tr>
<th>In-Check DIAL resistance setting</th>
<th>Covariates</th>
<th>Multivariable linear regression Standardized coefficient beta (95% CI)</th>
<th>R-squared statistic</th>
<th>AIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aerolizer®</td>
<td>FEV₁</td>
<td>18.0 (2.6, 34.3)</td>
<td>0.109</td>
<td>289.2</td>
</tr>
<tr>
<td>Diskus®</td>
<td>FEV₁</td>
<td>19.9 (6.8, 33.0)</td>
<td>0.172</td>
<td>271.3</td>
</tr>
<tr>
<td>Turbohaler®</td>
<td>FEV₁</td>
<td>11.8 (1.5, 22.0)</td>
<td>0.374</td>
<td>216.3</td>
</tr>
<tr>
<td></td>
<td>% predicted PEF</td>
<td>0.26 (0.01, 0.50)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: AIC, area inside the curve; PEF, peak expiratory flow; PIF, peak inspiratory flow.
smokers. The most prevalent comorbidity was hypertension (70%), followed by cardiovascular disease (ie, heart failure, arrhythmias, stroke or pulmonary or vascular disorders) (53%) and ischemic heart disease (IHD) (38%) (Supplementary material S2; Table 1). The mean (±SD) length of stay of index hospitalization was 8 (±2) days.

On admission to hospital, 24 (51%) patients were categorized as being on a high dose of ICS, and on discharge, this proportion reduced to 30%. The most prevalent COPD treatment combination was ICS plus a fixed dose of SABA/SAMA (30%), followed by a fixed dose of ICS/LABA plus LAMA (23%) (Supplementary material S2; Table 1). Of the 47 patients, 25 (53%) patients had stable COPD medication during the baseline year; 12 (26%) patients were prescribed additional medications (mainly ICS) during that time; five (11%) patients had at least one of their therapies dropped; three (6%) patients were not receiving any treatment and two (4%) patients had insufficient data to be categorized.

Figure 1 Participants’ flow diagram.

The majority of patients (89%) were admitted to the hospital for a Type 1 exacerbation, with 40 (85%) patients classified as GOLD (2017) group D and seven (15%) as group C. Overall, 31 (70%) patients had at least one moderate exacerbation during the baseline year. All patients had a hospitalization for a severe exacerbation during the baseline year, with 13 (30%) having two or more severe exacerbations during the baseline year (Supplementary material S2; Table 2). The mean FEV$_1$ was 39% predicted: only one (2%) patient was classified as “mild” with an FEV$_1$ ≥80% predicted, whereas 21 (45%) and 17 (36%) patients had “severe” and “very severe” airflow limitation, respectively (Supplementary material S2; Table 3).

Associations between spirometric parameters and PIF

For Aerolizer, Diskus and Turbohaler, significant univariate associations were noted between FEV$_1$ ($R$-squared values 0.109, 0.172 and 0.230, respectively), % predicted PEF ($R$-squared values 0.133, 0.134 and 0.294, respectively) and PIF (Table 1). Additionally, for Turbohaler, significant associations were also noted between % predicted FVC ($R$-squared value 0.151), % predicted FEV$_1$ ($R$-squared value 0.180) and log (FEF$_{25–75}$) ($R$-squared value 0.152) and PIF. Despite statistical significance, the $R$-squared statistics indicate that only a small proportion of variance could be explained by the covariates (Table 1). Regression results for Handihaler are not presented as data did not allow for adequate model fit, and changing to a binary logistic regression was not possible due to small numbers in the categories.

In multivariable analysis, FEV$_1$ was the only variable retained for Aerolizer and Diskus ($R$-squared values 0.109 and 0.172, respectively), whereas for Turbohaler, the best model for prediction of PIF included both FEV$_1$ and % predicted PEF, although the $R$-squared value (0.374)

### Table 3 Multivariable association of spirometric parameters and other variables with PIF through each In-Check™ DIAL resistance setting

<table>
<thead>
<tr>
<th>In-Check DIAL resistance setting</th>
<th>Covariates</th>
<th>Multivariable linear regression</th>
<th>R-squared statistic</th>
<th>AIC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Standardized coefficient beta (95% CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aerolizer®</td>
<td>FEV$_1$</td>
<td>17.0 (1.8, 32.2)</td>
<td>0.209</td>
<td>285.6</td>
</tr>
<tr>
<td></td>
<td>GERD</td>
<td>15.6 (2.3, 29.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diskus®</td>
<td>FEV$_1$</td>
<td>16.0 (3.8, 28.2)</td>
<td>0.350</td>
<td>263.9</td>
</tr>
<tr>
<td></td>
<td>Age</td>
<td>−0.91 (−1.5, −0.35)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IHD</td>
<td>10.5 (0.14, 20.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Turbohaler®</td>
<td>FEV$_1$</td>
<td>11.8 (1.5, 22.0)</td>
<td>0.374</td>
<td>216.3</td>
</tr>
<tr>
<td></td>
<td>% predicted PEF</td>
<td>0.26 (0.01, 0.50)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** AIC, area inside the curve; GERD, gastroesophageal reflux disease; IHD, ischemic heart disease; PEF, peak expiratory flow; PIF, peak inspiratory flow.
was not strong (Table 2). Thus, associations between PIF and spirometric parameters were either absent or, when present, weak, indicating that routine spirometry is not adequately able to serve as a surrogate for PIF against resistance.

Distributions of PIF by categorical baseline variables
PIF distributions by categorical baseline variables showed that higher median PIFs through at least one device appeared to be associated with male gender, current smokers and a diagnosis of gastroesophageal reflux disease (GERD), osteoporosis, IHD, diabetes or GOLD group (Supplementary material S2; Figures S1–S6 and S8). In contrast, patients in the highest mMRC category appeared to have lower median PIF through Aerolizer and Diskus than those in the lower mMRC categories (Supplementary material S2; Figure S7).

Correlations between PIF and continuous baseline variables
For all resistance settings, while there was a small positive correlation between PIF and % predicted PEF and FEV\textsubscript{1}, there was a negative correlation between PIF and age (Supplementary material S2; Figure S9A–D). Moreover, for Turbhaler only, PIF appeared to positively correlate with FEF\textsubscript{25–75}, % predicted FEV\textsubscript{1}, % predicted FVC and FEV\textsubscript{1}/FVC (Supplementary material S2; Figure S9D).

Associations between spirometric parameters, demographic and clinical characteristics and PIF
For Turbhaler, the final regression model was not improved by other covariates and so included only FEV\textsubscript{1} and % predicted PEF (R-squared value 0.374). For Aerolizer, in addition to FEV\textsubscript{1} as a covariate, diagnosis of GERD was significantly associated with higher PIF (R-squared value 0.209). For Diskus, the final multivariable model included FEV\textsubscript{1}, age and diagnosis of IHD (R-squared value 0.350). Older age was associated with lower PIF, whereas diagnosis of IHD was associated with higher PIF. However, R-squared values of the regression models for all three devices were weak (<0.4) (Table 3). Regression for Handihaler did not allow for adequate model fit and thus was not further analyzed.

Associations between PIF and follow-up events
There were no clear associations between PIF at discharge and time to acute exacerbation with hospitalization, time to acute exacerbation without a hospitalization or time free of exacerbations (Supplementary material S3; Figures S1–S3). PIFs <60 L/min were observed in 10 patients (21%) for Aerolizer, 17 patients (36%) for Diskus, 32 patients (68%) for Turbohaler and with PIFs <30 L/min in six patients (13%) for Handihaler (Supplementary material S2; Table 1). The number of patients readmitted to the hospital for acute exacerbations with PIF <60 and ≥60 L/min were as follows: for Aerolizer, 6 (13%) and 15 (32%), respectively; for Diskus, 9 (19%) and 12 (26%), respectively; for Turbohaler, 15 (32%) and 6 (13%), respectively, and with PIF <30 and ≥30 L/min, for Handihaler, it was 4 (9%) and 17 (36%), respectively (Supplementary material S3; Table 2). For all devices except Diskus, mean time to readmission was shorter in the higher PIF category, with Turbohaler appearing to have the largest difference in mean days to readmission (Supplementary material S3; Figure S4). For Aerolizer and Handihaler, the probability of remaining hospital-free following discharge seemed to be lower for patients with PIF <60 and <30 L/min, respectively, although this was not statistically significant (Supplementary material S3; Figure S5). There was no difference in the probability of remaining hospital-free between <60 and ≥60 L/min PIF groups for Turbohaler and Diskus. When the study sample was categorized by baseline COPD medication groups, median time to acute exacerbation with hospitalization seemed to be longest for patients who had a therapy added (n=12 [29%]) during the baseline year (123 days [IQR, 45–183]) and shortest for patients who had a therapy dropped (14 days [IQR, 11–53]) (Supplementary material S3; Table 3).

Discussion
This study among hospitalized COPD patients, to our knowledge, is the first to explore the relationship between PIF against DPI device resistance at the time of discharge and patient characteristics and lung function parameters as well as follow-up events. Although our study showed the feasibility of measuring PIF against DPI resistance in patients with COPD at discharge, no variable individually or in combination was useful in predicting those with low PIF against imposed resistance, suggesting that PIF against resistance needs to be measured directly.

The strength of the study lies in the fact that it is the first retrospective observational study to explore associations between a combination of baseline patient characteristics and spirometric parameters and PIFs through four different resistances corresponding to DPI devices at the time of
discharge. The study focused on a patient cohort at discharge following hospitalization for a severe COPD exacerbation, because DPIs are often prescribed without information on PIF for this population, an often elderly population with advanced stages of COPD, high symptom burden, multi-morbidity and at greatest risk of future exacerbations. Therefore, it was important to test the feasibility of measuring PIF through imposed resistance at the time of discharge in this vulnerable population. Finally, PIF measurements were obtained at discharge against four different resistance settings from RV, which is easier and practical to perform in clinical practice than from functional residual capacity.

The study found a small positive correlation between PIF and FEV₁ and % predicted PEF across all imposed resistance settings and, for three of the devices, also identified predictors of PIF though none were strong: Aerolizer (FEV₁ and diagnosis of GERD), Diskus (FEV₁, younger age and diagnosis of IHD) and Turbohaler (FEV₁ and % predicted PEF). Altogether, these findings strongly suggest that PIF against device resistance needs to be measured directly.

Previous studies have also found correlations between PIF and various spirometric parameters; however, correlations between PIF through resistance and both FEV₁ and % predicted FEV₁ have been shown to be inconsistent.²⁷,²⁸,³⁰,³² and hence, decision on inhaler device selection should not be based on FEV₁ alone. PIF and FEV₁ also reflect extrapulmonary and pulmonary dynamics, respectively, and hence our findings are not surprising. PIF is a marker of inspiratory muscle strength, which can improve significantly with endurance training.³⁸ Aging, arthritis and malnutrition can also contribute to reduced respiratory muscle strength, which reduces PIFs.³⁹,⁴⁰ Although no correlations were found between PIF and FVC in this study, reduced vital capacity has been shown to correlate with PIF in multiple studies, suggesting that other factors beyond airflow limitation, such as respiratory muscle insufficiency, hyperinflation or air trapping, may be good predictors of low PIF.²⁷,²⁸,³² Although increasing age²⁴,²⁶-³¹ and female gender²⁴,²⁸,³⁰,³² have consistently been shown to correlate with decreasing PIFs among COPD patients in general, no associations were found between gender and PIFs across resistances in this study. A possible explanation could be the predominance of males in our patient cohort, who have higher overall values for lung function including inspiratory mouth pressures than women,⁴¹ and thus with fewer females in our cohort we detected no significant correlations between female gender and decreasing PIF. In a recent study among COPD inpatients at discharge, pneumonia and IHD were found to be associated with lower PIFs through Diskus, which are inconsistent with our study findings that suggested that GERD and IHD were associated with higher PIFs using Aerolizer and Diskus, respectively. The clinical reasons for these findings are unclear and could be a reflection of confounders due to low sample size and/or multiple analysis effects. Future research studies that are adequately powered are needed to confirm our findings.

In this study, a cutoff at a PIF less than 30 L/min for Handihaler and PIF less than 60 L/min for Aerolizer, Diskus and Turbohaler were made in order to distinguish optimal flows from suboptimal levels based on a review of the current literature.²²,³⁵ Previous studies have measured PIF through different resistances mainly in clinically stable COPD patients and few studies have used similar cutoffs to this study.²⁷-³² In elderly, stable COPD patients, Janssens et al found that among 26 patients, 12.5% had suboptimal PIF (defined as <45 L/min) using Aerolizer, 20% using Diskus and 30% using Turbohaler, whereas Mahler et al found that among 213 patients, 19% had suboptimal PIF (defined as <60 L/min) using Diskus. In our inpatient cohort, the prevalence of suboptimal PIF through Aerolizer, Diskus and Turbohaler at discharge was higher than that observed in a previous study of clinically stable patients with severe COPD.²⁷ This reinforces the view that COPD exacerbations can significantly reduce PIF during the acute phase as hyperinflation is prevalent and inspiratory muscle function is often compromised,⁴⁰,⁴⁵ and while a reduced PIF may not vary substantially during the acute exacerbation time frame, this reduction may continue for a few months following discharge.³² Thus, PIF measurement at discharge plays a critical role in determining if an elderly patient can use or continue to use a particular DPI device, as their ability to generate sufficient inspiratory flow is often compromised following a COPD exacerbation.

This study found no strong associations between PIF through any of the resistance settings at the time of discharge and time to event outcomes. Furthermore, for all devices except for Diskus, the higher PIF group (while the lower PIF group for Diskus) appeared to have had fewer days to COPD readmission. These findings are inconsistent with those from a previous retrospective study, which found that the lower PIF group (defined as <60 L/min against zero resistance) had significantly fewer days to COPD readmission and that PIF was the only significant variable associated with readmission.²⁶ Additionally, our results seem to suggest that patients with Aerolizer PIF <60 L/min and patients with Handihaler PIF <30 L/min have a higher probability of being readmitted for an acute exacerbation. It is possible that our results could
devices in patients with COPD. Although PIF measurement against resistance would be a valuable addition to the standard of care in the management of COPD, it needs to be measured directly. Second, this study showed the feasibility of measuring PIF against resistance in patients with COPD at discharge. Further studies are needed to define the impact of PIF, device selection and outcomes after discharge following a COPD exacerbation.

Acknowledgments
This study was supported by AstraZeneca. The abstract of this paper was presented at the American Thoracic Society International Conference 2017 as a poster presentation with interim findings.

Disclosure
David B Price has board membership with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from Aerocrine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva (Sanofi Generics); payment for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Skyepharma, Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma, Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma, Novartis; payment for travel/accommodation/meeting expenses from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, Teva Pharmaceuticals; funding for patient enrollment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals, Zentiva (Sanofi Generics); stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte.
Ltd (Singapore); and is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment. David B Price is owner and managing director of Observational and Pragmatic Research Institute Pte Ltd. Simina Z Bosnic-Anticevich has received honoraria from AstraZeneca, GlaxoSmithKline and Pfizer. Vincent A R Tardif has received honoraria from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mundipharma and Teva Pharmaceuticals for her contribution to advisory boards/key international expert forum. Victoria Carter, Sen Yang, Antony Hardjojo and Simon Wan Yue Ming are employees of the Observational and Pragmatic Research Institute Pte Ltd, which has conducted paid research in respiratory disease on behalf of the following organizations in the past 5 years: Anaxys, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Circassia (formerly Aerocrine), GlaxoSmithKline, Harvey Walsh, Mapi, Morningside Healthcare, Mundipharma, Mylan (formerly Meda), Napp, Novartis, Orion, Plymouth University, Regeneron, Respiratory Effectiveness Group, Roche, Sanofi, Takeda, Teva, University of East Anglia, Zentiva (a Sanofi company). Paul M Dorinsky is an employee of Pearl – a member of the AstraZeneca Group. Claudia Cabrera is an employee of AstraZeneca. Andriana I Papaioannou and Stelios Loukides declare no relevant conflicts of interest. The authors report no other conflicts of interest in this work.

References


